Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120:1589–96.

Article  PubMed  Google Scholar 

Bazarbachi AH, Al Hamed R, Malard F, Bazarbachi A, Harousseau JL, et al. Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. Blood Cancer J. 2022;12:47.

Article  PubMed  PubMed Central  Google Scholar 

Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol J Am Soc Clin Oncol. 2007;25:2434–41.

Article  Google Scholar 

Villalba A, Gonzalez-Rodriguez AP, Arzuaga-Mendez J, Puig N, Arnao M, Arguiñano JM, et al. Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM). Leuk Lymphoma. 2022;63:3438–47.

Article  PubMed  CAS  Google Scholar 

Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol J Am Soc Clin Oncol. 2019;37:589–97.

Article  CAS  Google Scholar 

Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301–13.

Article  PubMed  CAS  Google Scholar 

Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936–45.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet Lond Engl. 2019;394:29–38.

Article  CAS  Google Scholar 

Byun JM, Park SS, Yoon SS, Ahn A, Kim M, Lee JY, et al. Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study. Blood Res. 2023;58:83–90.

Article  PubMed  PubMed Central  CAS  Google Scholar 

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 -. Identifier NCT04934475, Minimal Residual Disease Adapted Strategy (MIDAS); 2021; [about 4 screens]. Available from: https://clinicaltrials.gov/study/NCT04934475.